Menu Search
Equities

NuGen Medical Devices Inc

79O:STU

NuGen Medical Devices Inc

Actions
  • Price (EUR)0.0624
  • Today's Change0.003 / 4.70%
  • Shares traded1.00k
  • 1 Year change-31.80%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NuGen Medical Devices Inc. is a Canada-based specialty medical device company. The Company is engaged in marketing and selling its InsuJet needle-free injection system designed to improve the lives of millions of diabetics. Its principal business is the research, development and commercialization of needle-free injection devices and systems for the administration of subcutaneous medication. It is developing products using its needle-free delivery technology in several fields including, but not limited to, diabetes, semaglutide, growth and fertility hormone, as well as deoxyribonucleic acid (DNA) and conventional/pediatric vaccines. It is focusing its development efforts on needle free devices in the area of liquid jet delivery through the InsuJet platform. The Company's InsuJet technology platform is based on jet-stream administration of liquid drugs. The Company manufactures and commercializes needle-free injection systems and sells in over 40 countries globally.

  • Revenue in CAD (TTM)346.79k
  • Net income in CAD-7.63m
  • Incorporated2022
  • Employees12.00
  • Location
    NuGen Medical Devices Inc18 King Street East, Suite 1400Toronto M5C 1C4CanadaCAN
  • Phone+1 (647) 501-3290
  • Websitehttps://www.nugenmd.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.